Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.44B | $5.20B | $5.29B | $5.07B | $5.06B | $4.66B | $4.56B | $4.21B |
| Cost of revenue | $1.59B | $1.59B | $1.61B | $1.52B | $1.64B | $1.45B | $1.47B | $1.31B |
| Gross profit | $3.85B | $3.61B | $3.68B | $3.54B | $3.42B | $3.21B | $3.10B | $2.90B |
| Gross margin | 70.7% | 69.4% | 69.6% | 69.9% | 67.7% | 68.8% | 67.9% | 68.8% |
| Research and development | $554.00M | $516.00M | $569.00M | $514.00M | $526.00M | $443.00M | $459.00M | $407.00M |
| Selling, general and administrative | $1.80B | $1.78B | $1.83B | $1.74B | $1.72B | $1.60B | $1.61B | $1.56B |
| Operating expenses | $2.67B | $2.51B | $2.85B | $2.49B | $2.61B | $2.29B | $2.42B | $2.16B |
| Operating income | $1.18B | $1.10B | $825.00M | $1.05B | $819.00M | $921.00M | $675.00M | $733.00M |
| Operating margin | 21.6% | 21.2% | 15.6% | 20.7% | 16.2% | 19.8% | 14.8% | 17.4% |
| EBITDA | $1.62B | $1.43B | $1.53B | $1.38B | $1.32B | $1.34B | $1.19B | $1.05B |
| Interest expense | −$96.00M | −$90.00M | −$90.00M | −$87.00M | −$90.00M | −$82.00M | −$80.00M | −$79.00M |
| Income before taxes | $1.06B | $1.16B | $700.00M | $939.00M | $941.00M | $805.00M | $585.00M | $669.00M |
| Income taxes | $155.00M | −$176.00M | $30.00M | $183.00M | $146.00M | $133.00M | $23.00M | $200.00M |
| Net income | $905.00M | $1.34B | $670.00M | $756.00M | $795.00M | $672.00M | $562.00M | $469.00M |
| Net margin | 16.6% | 25.7% | 12.7% | 14.9% | 15.7% | 14.4% | 12.3% | 11.1% |
| EPS, basic | $0.62 | $0.90 | $0.45 | $0.51 | $0.54 | $0.46 | $0.38 | $0.32 |
| EPS, diluted | $0.61 | $0.90 | $0.45 | $0.51 | $0.53 | $0.45 | $0.38 | $0.32 |
| Diluted shares | 1.47B | 1.50B | 1.50B | 1.50B | 1.49B | 1.49B | 1.49B | 1.49B |
Figures describe Boston Scientific shares, not any token. As of Aug 3, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.